Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
Telescope Innovations Corp. (OTCQB: TELIF) regularly issues news and updates that highlight its progress in intelligent automation, Self-Driving Labs, and advanced chemical manufacturing technologies. Company announcements describe deployments of Self-Driving Labs for pharmaceutical research and education, development milestones in lithium processing technologies, and commercial traction for products such as DirectInject-LC™.
News releases detail Telescope’s installation of a pharmaceutical Self-Driving Lab for the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association in Seoul, which the company describes as Korea’s first Self-Driving Lab for pharmaceutical development and training. Other updates cover a multi-year, funded Self-Driving Lab development project with Pfizer and broader initiatives to expand SDL adoption across pharmaceuticals, industrial chemistry, energy, and agriculture.
Telescope’s news flow also includes information on its proprietary lithium technologies, including the ReCRFT™ process for producing battery-grade lithium carbonate from battery recycling brines and the DualPure™ process for low-temperature lithium sulfide production. The company reports government funding approvals to advance and scale these processes, as well as participation in the Arkansas Lithium Technology Accelerator to explore commercialization pathways with industry partners.
In addition, Telescope publishes updates on corporate developments such as stock option and restricted share unit grants, debt settlement transactions using common shares, and executive appointments that support its growth in online analytics and Self-Driving Lab deployments. Investors and followers of TELIF can use this news stream to monitor operational milestones, technology validation, partnerships, and capital markets activity described directly by the company.
Telescope Innovations (OTCQB: TELIF) has achieved a significant breakthrough in battery recycling technology, successfully producing battery-grade lithium carbonate with >99.9% purity from recycled battery waste streams using their proprietary ReCRFT™ process.
Building on their April 2024 proof-of-concept, the company has demonstrated the ability to extract and refine lithium from complex battery waste materials. The process addresses a crucial challenge in battery recycling, as lithium represents 16% to 55% of the total metal value in spent batteries.
The company has partnered with Cellmine and the University of St Andrews for testing and validation of the recycled lithium carbonate in actual battery applications, marking an important step toward sustainable battery materials sourcing.
Telescope Innovations (OTCQB: TELIF), a leader in intelligent automation platforms for chemical process development, has appointed Vaso Vlachos as Chief Operating Officer. With over 20 years of experience in automation and analytical technology for biopharmaceutical and chemical industries, Vlachos joins from Mettler-Toledo AutoChem where she served as Global Head of Real-Time Analytics.
The company's DirectInject-LC product has doubled in sales opportunities in Q3 2025 compared to Q3 2024, with operations expanding from North America to Europe, Japan, and China. Telescope is also advancing Self-Driving Lab deployments with partners like Pfizer and developing lithium refinement technologies.
Additionally, the company granted 518,140 stock options to employees and consultants, exercisable at $0.43 until September 2, 2030.
Telescope Innovations (OTCQB: TELIF), a chemical process development automation company, has been selected to join ALTA (Arkansas Lithium Technology Accelerator), America's first lithium technology accelerator. The company will collaborate with industry leaders like Standard Lithium, Albemarle, ExxonMobil, and Chevron.
Telescope brings two key technologies to ALTA: ReCRFT™, a low-capital method for producing battery-grade lithium carbonate, and DualPure™, a process for creating lithium sulfide for solid-state batteries. ReCRFT™ has been validated with feedstocks from over 8 North American sites, while DualPure™ samples are being evaluated by battery industry groups in North America and Asia.
This strategic engagement comes as Telescope prepares for pilot-scale deployment of its technologies, with ALTA providing direct access to leading lithium producers for technical collaboration and operational validation.
Telescope Innovations (OTCQB:TELIF), a developer of advanced technologies for pharmaceutical and chemical industries, reported its Q3 2025 financial results. The company achieved revenues of CAD $1.39 million, up from CAD $1.22 million in Q3 2024, with an adjusted EBITA loss of CAD $99,466.
The quarter saw strong performance of their DirectInject-LC™ product, with doubled opportunities compared to Q3 2024 and successful expansion into Asian markets. Telescope is finalizing a Phase 1 Self-Driving Lab platform with Pfizer and has shipped its first battery-grade lithium sulfide samples to major battery industry groups, leveraging its proprietary low-temperature production process.
The company maintains strategic partnerships with Mettler Toledo, Pfizer, and Standard Lithium, positioning itself for continued growth in analytical and automation innovations.Telescope Innovations Corp (TELIF) reported Q2 2025 financial results with revenues of $1.0 million, up from $686,205 in Q2 2024, and an adjusted EBITA loss of $441,837. Expenses increased to $1.7 million from $1.3 million year-over-year.
Key operational highlights include: expansion of DirectInject-LC™ product into China through Mettler Toledo partnership; development of EasyFrit sampling filter accessory; 33% team growth supporting Self-Driving Lab development with Pfizer; successful production of >99% pure battery-grade lithium carbonate using ReCRFT™ technology; and CTO Jason Hein receiving the 2025 R.U. Lemieux Award.
The company continues to reinvest revenues for operational growth, with results aligning with management's FY 2025 targets.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The event, scheduled for April 23, 2025, will feature a presentation by COO Dr. Jeffrey W. Sherman from 2:00-2:30 PM PST.
The company, which specializes in developing advanced technologies for pharmaceutical and chemical industries, will offer 1x1 investor meetings on April 24, 2025, at the Paris Hotel & Casino in Las Vegas. The presentation will be accessible via webcast.
Recent company achievements include:
- Advancement in Self-Driving Lab Deployment
- Master Collaborative Research Agreement with Pfizer
- Global distribution agreement with Mettler Toledo for DirectInject-LC™
- Frankfurt Stock Exchange listing
- CTO Professor Jason Hein's 2025 R. U. Lemieux Award
- Second Nobel Prize won by company advisor
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) provides an update on its Self-Driving Lab (SDL) technology development. SDLs combine AI, robotics, and advanced chemistry analytics to accelerate R&D processes 10-100 times faster than traditional methods.
The company has strengthened its position through a master collaborative agreement with Pfizer and becoming a Certified Systems Integrator with Universal Robots. Telescope has expanded its team by 33% over the past six months, enhancing expertise in chemistry, engineering, robotics, and AI-driven automation.
CTO Prof. Jason Hein has engaged with leading institutions including Seoul National University and Korean institutes to strengthen international partnerships. The company focuses on accelerating research in pharmaceuticals, industrial chemicals, and critical minerals, positioning itself to create value in the AI-powered scientific landscape.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) has announced its listing on the Frankfurt Stock Exchange (FSE) under the ticker symbol 'J4U'. This strategic move expands the company's visibility and accessibility to European investors, complementing its existing listings on the Canadian Securities Exchange and OTCQB.
The company operates at the intersection of AI, robotics, advanced analytics, and chemical process innovation, developing intellectual property and automation tools for research and manufacturing efficiency. Telescope serves the pharmaceutical, industrial chemical, and critical materials sectors through world-class partnerships and industry-leading customers.
The FSE listing is expected to increase trading liquidity and provide greater exposure to international investors, particularly in Europe's chemical and pharmaceutical industries where the company has established commercial relationships.
Telescope Innovations (CSE: TELI) (OTCQB: TELIF) announced that its Founder and Chief Technology Officer, Professor Jason Hein, has been awarded the 2025 R.U. Lemieux Award by the Chemical Institute of Canada. The award recognizes his contributions to organic chemistry and pioneering research in reaction mechanisms and process development.
Professor Hein leads Telescope's technological vision, focusing on reaction automation, AI-driven chemical research, and robotics for scalable, sustainable chemical manufacturing. His work aims to accelerate the development of next-generation processes for the pharmaceutical and fine chemical industries.
The R.U. Lemieux Award, presented by the Canadian Society for Chemistry, celebrates excellence in organic chemistry and recognizes distinguished contributions to the field.
FAQ
What is the current stock price of TELESCOPE INNOVATIONS (TELIF)?
What is the market cap of TELESCOPE INNOVATIONS (TELIF)?
